Tyra Biosciences Inc (TYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.62 Million) by net assets ($259.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Tyra Biosciences Inc (TYRA) strategic asset index to assess the company's strategic physical and investment asset allocation.
Tyra Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Tyra Biosciences Inc for net asset value and shareholders' equity analysis.
Tyra Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tyra Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pimco Dynamic Income Opportunities Fund
NYSE:PDO
|
0.276x |
|
Zymeworks Inc. Common Stock
NASDAQ:ZYME
|
-0.098x |
|
Inox Wind Limited
NSE:INOXWIND
|
-0.058x |
|
OVH Groupe SAS
PA:OVH
|
10.219x |
|
Beijer Alma AB (publ)
ST:BEIA-B
|
0.066x |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
0.055x |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
N/A |
|
Archi Indonesia Tbk PT
JK:ARCI
|
0.130x |
Annual Cash Flow Conversion Efficiency for Tyra Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tyra Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Tyra Biosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $259.18 Million | $-95.14 Million | -0.367x | -80.54% |
| 2024-12-31 | $343.15 Million | $-69.77 Million | -0.203x | +17.16% |
| 2023-12-31 | $204.26 Million | $-50.14 Million | -0.245x | -25.86% |
| 2022-12-31 | $257.83 Million | $-50.28 Million | -0.195x | -147.84% |
| 2021-12-31 | $301.74 Million | $-23.75 Million | -0.079x | -113.82% |
| 2020-12-31 | $-13.64 Million | $-7.76 Million | 0.569x | +3.08% |
| 2019-12-31 | $-4.74 Million | $-2.62 Million | 0.552x | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more